It starts in the lymphocytes, a type of white blood cell, and typically forms tumours in the lymph nodes. The two main types are Multiple myeloma is cancer of the plasma cells in the bone marrow.

Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

Johnson & Johnson (NYSE:JNJ) and Legend Biotech (NASDAQ:LEGN) said a long-term study showed their cell therapy Carvykti ...

Johnson & Johnson reports positive results for Talvey in combination with Darzalex Faspro, pomalidomide and Tecvayli in the ...

Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other ...